For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Testing The Addition Of Nivolumab To Chemotherapy In Treatment Of Soft Tissue Sarcoma
To compare treatment with chemotherapy (paclitaxel) alone to using a combination of nivolumab plus chemotherapy (paclitaxel) treatment in patients with angiosarcoma who have not been treated with paclitaxel chemotherapy alone.
DiagnosisPatient has a type of cancer called angiosarcoma
Cutaneous or visceral angiosarcoma
No prior PD-1, or VEGF TKI, PS 0-1
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Group 1: In Arm 1, participants will receive combination of paclitaxel and nivolumab. Participants assigned to Arm 2, will only receive paclitaxel.
- Group 2: Patients who have been treated with "taxane" chemotherapy. In this group, participants will receive a combination of cabozantinib and nivolumab.
For more information, visit ClinicalTrials.gov